Background: To explore a new schedule of gemcitabine-cisplatin (GP) combination therapy using two different cisplatin doses in patients with advanced non-small-cell lung cancer (NSCLC).
Introduction
In recent years, the role of chemotherapy in non-smallcell lung cancer (NSCLC) appears to have been sufficiently established. In advanced NSCLC a meta-analysis has demonstrated a small but significant 10% survival benefit at one year with cisplatin-containing regimens, thus favoring chemotherapy, in comparison to locoregional treatment or best supportive care [1] . Accordingly, cisplatin-containing regimens are currently considered the best treatment of advanced NSCLC, although remaining unsatisfactory because of treatment morbidity and marginal impact on survival (2) .
A series of new agents such as taxanes, vinorelbine, camptothecins, and gemcitabine have demonstrated significant activity in NSCLC. The combination of these new agents with cisplatin appears superior in terms of activity to the older regimens (i.e., cisplatin-etoposide, mitomycin C-vinblastine-cisplatin, mitomycin C-ifosfamide-cisplatin) with an average response rate ranging from 22% to 47%, as reported in a recent review [3] . These data have been at least in part confirmed by the first large completed randomized phase III trials [4] [5] [6] [7] [8] .
The gemcitabine-cisplatin combination has been studied extensively in phase II studies in over 300 patients with different schedules and a response rate ranging between 26% and 54% [9] [10] [11] [12] [13] [14] .
In vitro data have shown a different level of synergism between gemcitabine and cisplatin when temporal drug exposure and drug schedule varied, indicating the relevant role of dose scheduling in this combination [15] . In addition, when gemcitabine was given 24 hours before cisplatin it showed the highest in vivo anlitumor activity, postulating that pre-incorporation of gemcitabine allows the best synergy with cisplatin, thus increasing the formulation of cisplatin-DNA adducts and inhibiting the DNA repair mechanism of platinum-induced damage. However, this schedule was also associated with the worst toxicities observed in animal models [16] .
Interestingly, in a recent investigation [17] 4 different schedules of gemcitabine and cisplatin were applied in 33 patients with advanced stage solid tumors. Of all schedules, the treatment of patients with cisplatin 24 hours before gemcitabine gave the highest dFdCTP (gemcitabine-triphosphate) accumulation in white blood cells (WBC) and total platinum levels in plasma. Whether these pharmacokinetic findings led to a higher therapeutic index remains unclear.
On the basis of these considerations, in a phase II trial [9] and in the subsequent phase III study [8] , we administered to patients with unresectable locally advanced or metastatic NSCLC gemcitabine weekly on days 1, 8 and 15 and cisplatin on day 2 of a 28-day schedule reporting a response rate of 54% and 38% and median survival time of 61.5 and 34 weeks, respectively. In both trials, grade 3-4 thrombocytopenia was observed in 52% and 64% of patients, respectively, causing substantial reduction of planned gemcitabine dose intensity due to dose reductions and omissions (approximately 50% of all theoretical doses in both trials) on day 15. In the phase III study, dose reductions and omissions translated into a 30% reduction of the planned dose intensity for gemcitabine.
In the attempt to improve efficacy and reduce toxicity of the gemcitabine-cisplatin combination, Spanish investigators [4] explored in a randomized trial a threeweek schedule delivering 1250 mg/m 2 gemcitabine on days 1 and 8, and cisplatin 100 mg/m 2 on day 1. The data showed a statistically significant higher response rate (40.6% versus 21.9%, P < 0.02) and longer time to progression (6.9 versus 4.3 months, P = 0.01) for the gemcitabine-cisplatin regimen compared to the cisplatin-etoposide one. The toxicity profile of gemcitabinecisplatin administered every 21 days was quite comparable to that of cisplatin and etoposide.
Based on these data, in the present study we evaluated the activity and toxicity of the gemcitabine-cisplatin regimen on a 21-day schedule, omitting the administration of gemcitabine on day 15, with the aim of reducing the incidence of grade 3-4 thrombocytopenia. Gemcitabine was given on days 1 and 8 and cisplatin on day 2 every 3 weeks, also testing two different cisplatin dose levels of 100 and 70 mg/m 2 , respectively. The two platinum dose levels were planned in order to evaluate the activity of a lower dose, with the aim of a possible reduction of toxicity, also taking into consideration two previous randomized trials that did not show any significant advantage in activity and efficacy by increasing cisplatin dose-intensity and any evidence of a dose-response relationship for cisplatin in advanced NSCLC [18, 19] . On the other hand, only one randomized trial has shown a statistically significant improvement in median duration of response and in median survival from the use of a cisplatin higher dose (120 mg/m 2 ) compared with a lower dose (60 mg/m 2 ) [20] .
Patients and methods
From May to December 1997, 92 patients with unresectable locally advanced or metastatic NSCLC from 6 Italian institutions entered this multicenter phase II randomized trial. Eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) PS < 2 . no previous chemotherapy, measurable or evaluable disease, leukocyte count ^ 3.5 x 10 9 /l, platelet count ^ 100 x 1O 9 /1, hemoglobin level > 10 g/1, serum creatinine level ^1.5 mg/dl, no active infection, and no severe concurrent medical condition. Prior radiation therapy was allowed as long as the irradiated area was not the only source of measurable or evaluable disease. Patients with brain metastases were enrolled if their condition did not require emergency radiotherapy treatment.
Pretreatment evaluation included a computed tomography (CT) scan of the chest and upper abdomen, chest X-ray and, optionally, upper abdominal ultrasonography. Brain CT and bone scans were performed only if there was clinical suspicion of metastases. Complete blood cell counts were repeated on days 1 and 8 of each cycle; serum chemistry was performed on day 1.
Patients were randomly assigned to receive cisplatin on day 2 at a dose of 100 mg/m 2 in arm A or 70 mg/m 2 in arm B; in both arms gemcitabine 1,000 mg/m 2 was administered on days 1 and 8 of each treatment course. Courses were repeated every three weeks up to six cycles. Before cisplatin administration patients received intravenous hydration with 1500 ml normal saline supplemented with 20 mEq potassium chloride over 90 minutes followed by 250 ml mannitol 18% solution and 1,000 ml normal saline, given over 2 hours. Cisplatin infusion was usually preceded by intravenous administration of a 5-HT3 receptor antagonist plus corticosteroids; prophylactic antiemetic steroids were not routinely administered on the day of gemcitabine administration. Treatment was discontinued due to disease progression, major toxicities, or according to the patient's or physician's decision.
Gemcitabine was reduced by 75% if the leukocyte count was 2.0 to 2.9 x 10 9 /l and/or the platelet count was between 50 and 99 x 10 9 /l at the time of drug administration. Gemcitabine was omitted if the leukocyte count was < 2 x 10 9 /l and/or the platelet count was <50xl0 9 /l.
At baseline, tumor lesions were categorized as follows: measurable (lesions that can be accurately measured in at least one dimension) or evaluable (all other lesions). Patients having the only lesion in previously irradiated fields, or as ascites, pleural/pericardial effusion, leptomeningeal disease, or bone metastases were considered to have a non-measurable and non-evaluable disease and were excluded from the trial.
Response to therapy was assessed by computed tomographic scans every two treatment courses according to the World Health Organization (WHO) criteria [21] ; toxicities were evaluated during each course and graded according to the WHO toxicity scale. Complete response (CR) was defined as the complete disappearance of all tumor lesions for at least four weeks. Partial response (PR) was defined as a reduction of > 50% in the product of the longest perpendicular diameters of the lesions. All other patients were considered nonresponders.
Statistical analysis
This randomized phase II trial was treated statistically as two simultaneous phase II studies: the Simon two-stage design was applied separately for each arm [22] , Survival was estimated by the product limit method of Kaplan and Meier and log-rank test. The z 2 -test with Yates' correction and Fisher's exact test were used to evaluate the balance of prognostic factors between the two arms, as well as to compare the frequency of side-effects.
Patients qualified for safety analysis if they received at least one full course of therapy. Responses and survival were determined for all eligible patients. Duration of response and survival were calculated from the beginning of chemotherapy.
Results
Ninety-two patients were randomized: 47 in arm A and 45 in arm B. Two patients were found ineligible after randomization (one each in arms A and B) because of diagnosis of small cell lung cancer in one case and nonmeasurable disease in the other (the patient had only 28 (18) 27 (18) 10 (6) 1 (1) 25 (16) 33 (21) 18 (12) 4 (3) 21 (14) 13 (8) 19 (12) 17 (11) 50 (28) 25 (14) 10 (6) 0 32 (18) 26 (15) 6 (3) 1 (1) 27 (15) 21 (12) 19 (11) 11 (6) Twelve patients were transfused with packed red blood cells in arm A and five in arm B; six patients received platelet transfusions in arm A and one in arm B. delivered to the brain sequentially to chemotherapy, after obtaining a partial remisssion. After a median follow-up of 27.6 months (range 24-31 months), the median duration of response was 9.7 months (range, 1.8 to 30.9 months) for the whole group (13.1 months and 9.5 months for arm A and B, respectively; P = 0.29, log-rank test). Median survival duration was 12 months (range 0.2 to 31.1 months) for the whole group (15.4 months and 11.5 months for arm A and B, respectively; P = 0.14, log-rank test). The one-year survival rate was 50% (53% in arm A and 46% in arm B). microscopic residual disease after surgery). These ineligible patients and two additional patients who did not receive study treatment because of refusal (one each in arms A and B) were excluded from subsequent analyses. Consequently, a total of 88 patients (45 in arm A and 43 in arm B) were fully evaluable. Patient characteristics were well balanced between the two arms and are summarized in Table 1 . Median age was 63 in arm A and 62 in arm B. The most common histology was adenocarcinoma. Sixty (68%) patients had stage IV disease and sixteen (18%) had brain metastases. Nearly all randomized patients were fully ambulatory (90% PS 0 1). Table 2 summarizes the response evaluation. Of 88 evaluable patients, two (4%) (arm A) had histologically confirmed CR, assessed by surgery received at the end of chemotherapy. No complete responses were observed in arm B. Thirty-seven (42%) patients achieved PR (17 in arm A and 20 in arm B). Overall response rates for arms A and B were 42% (95% CI: 27.8%-56.7%) and 47% (95% CI: 31.6%-61.5%), respectively. Eight of sixteen patients (50%) with brain metastases achieved PR of the brain lesions (3 of 6 patients in arm A, and 5 of 10 patients in arm B). In only one patient was radiotherapy Toxicity A total of 330 chemotherapy courses were administered (154 in arm A and 176 in arm B) with a median of three and five courses in arms A and B, respectively. Grade 3-4 thrombocytopenia was recorded in 23% of courses in arm A and 17% of courses in arm B. Grade 3-4 leukopenia occurred in 15% and 4% of courses (P -0.0019) and anemia in 7% and 6% of courses for arms A and B, respectively. Twelve patients (27%) in arm A were transfused with packed red blood cells as were five patients (12%) in arm B (P -0.07). Six (13%) and one (2%) patient received platelet transfusions in arms A and B (P -0.06), respectively (Tables 3-4) .
Planned gemcitabine administrations were 308 in arm A and 352 in arm B. Ten percent of gemcitabine doses were reduced in arm A and 4% were reduced in arm B; 8% of doses were omitted in arm A and 6% in arm B. Hematologic toxicity was the most common reason for dose reduction or omission.
The patients in arm A received 79% of the intended gemcitabine dose intensity and 88% of the intended cisplatin dose intensity over the full course of the treatment. Patients in arm B received 88% of the intended gemcitabine dose intensity and 98% of the intended cisplatin dose intensity (Table 5) . Table 6 summarizes non-hematologic toxicities per patient. Nine (20%) and three (7%) patients experienced grade 3-4 nausea and/or vomiting in arms A and B, respectively. Grade 2-3 alopecia was reported in 11 (24%) and 16 (37%) patients in arms A and B, respectively. Grade 1-2 nephrotoxicity occurred in 9 patients (20%) in arm A and in 3 (7%) in arm B, with one grade 4 episode in arm A.
Five patients discontinued treatment because of renal toxicity: four in arm A (one patient with grade 4 and three patients with grade 2 toxicities) and one in arm B (grade 2 toxicity). Two patients (one in each arm) refused treatment because of grade 3 vomiting. Treatment was discontinued because of hematologic toxicity in four patients in arm A (three patients with grade 4 and one patient with grade 3 myelotoxicity) and in one patient in arm B (grade 4). The latter patient (arm B) died of septic shock associated with grade 4 neutropenia and thrombocytopenia; he had received palliative radiotherapy just before chemotherapy (Table 7) .
Discussion
Among the last generation regimens proposed for the treatment of advanced NSCLC the gemcitabine-cisplatin doublet is one of the most active, with a response rate ranging from 26% to 54% in phase II studies [9] [10] [11] [12] [13] [14] . In all trials, gemcitabine was usually administered on a weekly basis for two or three weeks while the cisplatin schedule varied. Different schedules seem to influence toxicity, mainly myelotoxicity, with grade 3 and 4 neutropenia being more common when cisplatin was given on day 15 and thrombocytopenia more common when cisplatin was given on days 1 or 2 (Table 8 ).
In our previous phase II [9] and III [8] studies gemcitabine 1000 mg/m 2 was given on days 1, 8, 15 and cisplatin 100 mg/m 2 on day 2. In the randomized trial [8] gemcitabine-cisplatin was compared to MIC (mitomycin C, ifosfamide, cisplatin) in 307 chemonaive patients. Response rate was significantly higher in the cisplatin-gemcitabine (GP) arm (38% vs. 26%; P = 0.03), with a median survival time of 8.6 vs. 9.6 months, respectively. Myelosuppression was the main side effect with grade 3-4 thrombocytopenia and neutropenia occurring in 64% and 40% of the patients in the GP arm, and 28% and 34% in the MIC arm, respectively. This thrombocytopenia made necessary a gemcitabine dose reduction and omission which translated into a substantial reduction of planned dose-intensity for gemcitabine (70% of intended dose-intensity).
The present phase II randomized trial shows the feasibility of a 21-day schedule for gemcitabine and cisplatin, while maintaining the planned dose intensity for both drugs. Patients on arm A received 79% of the intended gemcitabine dose intensity and 88% of the intended cisplatin dose intensity; patients on arm B received 88% of the intended gemcitabine dose-intensity and 98% of the intended cisplatin dose-intensity. The results of this trial also indicate that both schedules are active, with overall response rates of 42% (95% CI: 27.8%-56.7%) for arm A and 47% (95% CI: 31.6%-61.5%) for arm B, and a median duration of response of 9.7 months (range, 1.8 to 30.9 months) for the whole group (13.1 months and 9.5 months for arm A and B, respectively; P -0.29, log-rank test). Median survival duration was 12 months (range 0.2 to 31.1 months) for the whole group (15.4 months and 11.5 months for arm A and B, respectively; P = 0.14, log-rank test). These results are comparable to those obtained in trials utilizing the 28-day schedule. In our previous phase II and Ill studies utilizing the 28-day schedule we obtained a response rate of 54% and 38% and a median survival time of 15.3 and 8.6 months, respectively. The 21-day schedule used in this study caused mild myelosuppression with grade 3-4 leukopenia affecting 36% of patients in arm A and in 11% of patients in arm B, and grade 3-4 thrombocytopenia affecting 44% of patients in arm A and 35% of patients in arm B. Thrombocytopenia did not lead to any clinical complication and did not influence the planned drug administration. A higher cisplatin dose also influenced hematologic toxicity in terms of transfusion burden: 12 patients (27%) were transfused with packed red blood cells in arm A as were five patients (12%) in arm B (P -0.07). Six (13%) and one (2%) patient received platelet transfusions in arm A and B (P = 0.06), respectively.
These findings compare favorably with our previous phase II and III experiences utilizing the 28-day schedule: in both, grade 3-4 thrombocytopenia was observed in 52% and 64% of patients, respectively, causing a significant reduction of gemcitabine planned dose intensity due to dose reductions and omissions on day 15, which translated into a 30% reduction of planned dose intensity for gemcitabine in the phase III study.
In conclusion, both 21-day schedules are active and show a reduction in myelotoxicity compared to that previously observed in the 28-day schedule of the gemcitabine-cisplatin combination, mainly in the group of patients treated with the lower cisplatin dose.
Notwithstanding the limitations of a phase II trial, these results are encouraging and worthy of further confirmation. Accordingly, we planned a phase III randomized study utilizing the 21-day schedule of cisplatin 75 mg/m 2 and gemcitabine 1250 mg/m 2 . compared to other platinum-containing regimens (paclitaxel plus carboplatin and cisplatin plus vinorelbine). The doses of cisplatin and gemcitabine of this phase III study were modified with respect to the present experience with the intention to maintain the planned dose-intensity of our previous phase III trial [8] . The planned accrual of 600 patients was completed in May 2000. Hopefully, the results of this trial will help to define the best chemotherapy regimen in advanced NSCLC.
